Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 11, Issue 6, 2015, Pages 1299-1308

  Sepúlveda Crespo, Daniel ^a   Serramía, María Jesús ^a   Tager, Andrew M ^b,c   Vrbanac, Vladimir ^b,c   Gómez, Rafael ^d   De La Mata, Francisco Javier ^d   Jiménez, José Luis ^a   Muñoz Fernández, Ma Ángeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^d UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Carbosilane dendrimer; HIV 1 prevention; Humanized BLT mice; Microbicide; Nanotechnology

Indexed keywords

ANTIVIRAL AGENTS; DENDRIMERS; DISEASE CONTROL; MAMMALS; NANOTECHNOLOGY; SILICA; VIRUSES;

ANTI-HIV-1 ACTIVITY; CARBOSILANE DENDRIMER; HIV INFECTION; HIV-1 PREVENTION; HUMANIZED BLT MICE; MICROBICIDE; SECOND GENERATION; VIRAL REPLICATION;

DISEASES;

ANTIVIRUS AGENT; CD4 ANTIGEN; G 2S 16; GLYCOPROTEIN GP 120; UNCLASSIFIED DRUG; ALKANESULFONIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DENDRIMER; G2-S16 COMPOUND; ORGANOSILICON DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INFECTION PREVENTION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN INTERACTION; SEXUAL TRANSMISSION; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS REPLICATION; ANIMAL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TRANSMISSION; VAGINA;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ALKANESULFONATES; ANIMALS; ANTI-HIV AGENTS; DENDRIMERS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MICE; ORGANOSILICON COMPOUNDS; VAGINA;

EID: 84937109836     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2015.04.013     Document Type: Article

References (36)

1. Cottrell M.L., Kashuba A.D. Topical microbicides and HIV prevention in the female genital tract. J Clin Pharmacol 2014, 54:603-615.
2. Scordi-Bello I.A., Mosoian A., He C., Chen Y., Cheng Y., Jarvis G.A., et al. Candidate sulfonated and sulfated topical microbicides: comparison of anti-human immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005, 49:3607-3615.
3. Tyssen D., Henderson S.A., Johnson A., Sterjovski J., Moore K., La J., et al. Structure activity relationship of dendrimer microbicides with dual action antiviral activity. PLoS One 2010, 5:e12309-e12324.
4. Abdool Karim S.S., Baxter C. Overview of microbicides for the prevention of human immunodeficiency virus. Best Pract Res Clin Obstet Gynaecol 2012, 26:427-439.
5. Chonco L., Pion M., Vacas E., Rasines B., Maly M., Serramia M.J., et al. Carbosilane dendrimer nanotechnology outlines of the broad HIV blocker profile. J Control Release 2012, 161:949-958.
6. Galan M., Sanchez Rodriguez J., Jimenez J.L., Relloso M., Maly M., de la Mata F.J., et al. Synthesis of new anionic carbosilane dendrimers via thiol-ene chemistry and their antiviral behaviour. Org Biomol Chem 2014, 12:3222-3237.
7. Vacas Cordoba E., Arnaiz E., Relloso M., Sanchez-Torres C., Garcia F., Perez-Alvarez L., et al. Development of sulphated and naphthylsulphonated carbosilane dendrimers as topical microbicides to prevent HIV-1 sexual transmission. AIDS 2013, 27:1219-1229.
8. Rasines B., Sanchez-Nieves J., Maiolo M., Maly M., Chonco L., Jimenez J.L., et al. Synthesis, structure and molecular modelling of anionic carbosilane dendrimers. Dalton Trans 2012, 41:12733-12748.
9. Brainard D.M., Seung E., Frahm N., Cariappa A., Bailey C.C., Hart W.K., et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol 2009, 83:7305-7321.
10. Wheeler L.A., Trifonova R., Vrbanac V., Basar E., McKernan S., Xu Z., et al. Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. J Clin Invest 2011, 121:2401-2412.
11. Wheeler L.A., Vrbanac V., Trifonova R., Brehm M.A., Gilboa-Geffen A., Tanno S., et al. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol Ther 2013, 21:1378-1389.
12. Garcia-Merino I., de Las Cuevas N., Jimenez J.L., Gallego J., Gomez C., Prieto C., et al. The Spanish HIV BioBank: a model of cooperative HIV research. Retrovirology 2009, 6:27-32.
13. Sepulveda-Crespo D., Lorente R., Leal M., Gomez R., De la Mata F.J., Jimenez J.L., et al. Synergistic activity profile of carbosilane dendrimer G2-STE16 in combination with other dendrimers and antiretrovirals as topical anti-HIV-1 microbicide. Nanomedicine 2014, 10:609-618.
14. Wu L., Martin T.D., Vazeux R., Unutmaz D., KewalRamani V.N. Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission. J Virol 2002, 76:5905-5914.
15. Eckstein P., Jackson M.C., Millman N., Sobrero A.J. Comparison of vaginal tolerance tests of spermicidal preparations in rabbits and monkeys. J Reprod Fertil 1969, 20:85-93.
16. Boutwell C.L., Rowley C.F., Essex M. Reduced viral replication capacity of human immunodeficiency virus type 1 subtype C caused by cytotoxic-T-lymphocyte escape mutations in HLA-B57 epitopes of capsid protein. J Virol 2009, 83:2460-2468.
17. Marechal V., Clavel F., Heard J.M., Schwartz O. Cytosolic Gag p24 as an index of productive entry of human immunodeficiency virus type 1. J Virol 1998, 72:2208-2212.
18. Shattock R.J., Rosenberg Z. Microbicides: topical prevention against HIV. Cold Spring Harb Perspect Med 2012, 2:a007385-a007402.
19. Shen R., Richter H.E., Smith P.D. Interactions between HIV-1 and mucosal cells in the female reproductive tract. Am J Reprod Immunol 2014, 71:608-617.
20. Dimitrov D.S., Willey R.L., Sato H., Chang L.J., Blumenthal R., Martin M.A. Quantitation of human immunodeficiency virus type 1 infection kinetics. J Virol 1993, 67:2182-2190.
21. Ensign L.M., Cone R., Hanes J. Nanoparticle-based drug delivery to the vagina: A review. J Control Release 2014, 190:500-514.
22. Kumar L., Verma S., Prasad D.N., Bhardwaj A., Vaidya B., Jain A.K. Nanotechnology: A magic bullet for HIV AIDS treatment. Artif Cells Nanomed Biotechnol 2014, 43:71-86.
23. Huskens D., Vermeire K., Profy A.T., Schols D. The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1. Antiviral Res 2009, 84:38-47.
24. Micsenyi A.M., Zony C., Alvarez R.A., Durham N.D., Chen B.K., Klotman M.E. Postintegration HIV-1 infection of cervical epithelial cells mediates contact-dependent productive infection of T cells. J Infect Dis 2013, 208:1756-1767.
25. Haase A.T. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010, 464:217-223.
26. Lekutis C., Olshevsky U., Furman C., Thali M., Sodroski J. Contribution of disulfide bonds in the carboxyl terminus of the human immunodeficiency virus type I gp120 glycoprotein to CD4 binding. J Acquir Immune Defic Syndr 1992, 5:78-81.
27. Hoglund S., Ofverstedt L.G., Nilsson A., Lundquist P., Gelderblom H., Ozel M., et al. Spatial visualization of the maturing HIV-1 core and its linkage to the envelope. AIDS Res Hum Retrovir 1992, 8:1-7.
28. Bobardt M.D., Cheng G., de Witte L., Selvarajah S., Chatterji U., Sanders-Beer B.E., et al. Hepatitis C virus NS5A anchor peptide disrupts human immunodeficiency virus. Proc Natl Acad Sci U S A 2008, 105:5525-5530.
29. Mauck C., Rosenberg Z., Van Damme L. Recommendations for the clinical development of topical microbicides: an update. AIDS 2001, 15:857-868.
30. Ndesendo V.M., Pillay V., Choonara Y.E., Buchmann E., Bayever D.N., Meyer L.C. A review of current intravaginal drug delivery approaches employed for the prophylaxis of HIV/AIDS and prevention of sexually transmitted infections. AAPS PharmSciTech 2008, 9:505-520.
31. Zussman A., Lara L., Lara H.H., Bentwich Z., Borkow G. Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 2003, 17:653-661.
32. Permanyer M., Ballana E., Este J.A. Endocytosis of HIV: anything goes. Trends Microbiol 2010, 18:543-551.
33. Gringhuis S.I., van der Vlist M., van den Berg L.M., den Dunnen J., Litjens M., Geijtenbeek T.B. HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. Nat Immunol 2010, 11:419-426.
34. Felts R.L., Narayan K., Estes J.D., Shi D., Trubey C.M., Fu J., et al. 3D visualization of HIV transfer at the virological synapse between dendritic cells and T cells. Proc Natl Acad Sci U S A 2010, 107:13336-13341.
35. Wiley R.D., Gummuluru S. Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci U S A 2006, 103:738-743.
36. Sepulveda-Crespo D., Sánchez-Rodríguez J., Serramía M.J., Gomez R., la Mata FJ De, Jimenez J.L., et al. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission. Nanomedicine (Lond) 2015, 10:899-914.